Abstract #347: Correlation of Serum Levels of Pro-insulin With Tumor Size of Insulinomas: Two Case Reports

2006 ◽  
Vol 12 ◽  
pp. 9
Author(s):  
Marielba Agosto Mujica
Keyword(s):  
Tumor Size ◽  
Case Reports ◽  
Serum Levels

scholarly journals Primary Oral Malignant Melanoma: Two Case Reports and Review of Literature

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Neeraj Sharma
Keyword(s):  
Malignant Melanoma ◽  
Early Detection ◽  
Oral Cavity ◽  
Tumor Size ◽  
Malignant Tumors ◽  
Case Reports ◽  
Review Of Literature ◽  
Oral Region ◽  
Rare Neoplasm ◽  
Oral Malignant Melanoma

Primary malignant melanoma of the oral cavity is a rare neoplasm. The tumors tend to metastasize or locally invade tissue more readily than other malignant tumors in the oral region. The survival of patients with mucosal melanomas is less than for those with cutaneous melanomas. Tumor size and metastases are related to the prognosis of the disease. Early detection, therefore, is important.

scholarly journals Synovial Sarcoma of the Nerve—Clinical and Pathological Features: Case Series and Systematic Review

Neurosurgery ◽  
2019 ◽  
Vol 85 (6) ◽  
pp. E975-E991 ◽  
Author(s):  
Stephen Shelby Burks ◽  
Ross C Puffer ◽  
Iahn Cajigas ◽  
David Valdivia ◽  
Andrew E Rosenberg ◽  
...  
Keyword(s):  
Systematic Review ◽  
Statistical Analysis ◽  
Synovial Sarcoma ◽  
Tumor Size ◽  
Clinical Course ◽  
Case Reports ◽  
Case Series ◽  
Pathological Features ◽  
Eligibility Criteria

Abstract BACKGROUND Synovial sarcoma of the nerve is a rare entity with several cases and case series reported in the literature. Despite an improved understanding of the biology, the clinical course is difficult to predict. OBJECTIVE To compile a series of patients with synovial sarcoma of the peripheral nerve (SSPN) and assess clinical and pathological factors and their contribution to survival and recurrence. METHODS Cases from 2 institutions collected in patients undergoing surgical intervention for SSPN. Systematic review including PubMed and Scopus databases were searched for related articles published from 1970 to December 2018. Eligibility criteria: (1) case reports or case series reporting on SSPN, (2) clinical course and/or pathological features of the tumor reported, and (3) articles published in English. RESULTS From patients treated at our institutions (13) the average follow-up period was 3.2 yr. Tumor recurrence was seen in 4 cases and death in 3. Systematic review of the literature yielded 44 additional cases with an average follow-up period of 3.6 yr. From pooled data, there were 10 recurrences and 7 deaths (20% and 14%, respectively). Adjuvant treatment used in 62.5% of cases. Immunohistochemical markers used in diagnosis varied widely; the most common are the following: Epithelial membrane antigen (EMA), cytokeratin, vimentin, cluster of differentiation (CD34), and transducin-like enhancer of split 1 (TLE1). Statistical analysis illustrated tumor size and use of chemotherapy to be negative predictors of survival. No other factors, clinically or from pathologist review, were correlated with recurrence or survival. CONCLUSION By combining cases from our institution with historical data and performing statistical analysis we show correlation between tumor size and death.

Celiac Disease and Sensitization to Wheat, Rye, and Barley: Should We Be Concerned?

2020 ◽  
pp. 1-7
Author(s):  
Camila Marques de Valois Lanzarin ◽  
Natalia de Oliveira e Silva ◽  
Maissara Obara Venturieri ◽  
Dirceu Solé ◽  
Ricardo Palmero Oliveira ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Small Bowel ◽  
Case Reports ◽  
Serum Levels ◽  
Specific Ige ◽  
Age At Diagnosis ◽  
Gluten Free ◽  
Small Bowel Biopsy ◽  
History Of ◽  
Ige Mediated

<b><i>Background:</i></b> Concomitance of celiac disease (CD) and IgE-mediated wheat allergy is described in some case reports. The objective was to evaluate the frequency of sensitization to wheat, rye, barley, and malt in children and adolescents with CD. <b><i>Methods:</i></b> Measurement of serum levels of specific IgE to wheat, rye, barley, and malt (ImmunoCAP; sensitization IgE ≥0.35 kUA/L) in CD patients followed in specialized clinics to verify allergy history, general characteristics, small bowel biopsy characteristics, compliance with gluten-free diet (GFD), and occurrence of symptoms in case of noncompliance. <b><i>Results:</i></b> We evaluated 74 patients; the median of age and age at diagnosis of CD were 8.6 years (5.0–12.8) and 3.6 years (1.6–7.0), respectively. Median time of GFD was 3.5 years (1.4–5.8). History of asthma occurred in 17.3% of subjects, allergic rhinitis in 13.5%, and AD in 5.4%. Frequency of sensitization was 4% for wheat, 10.8% for rye, 5.4% for barley, and 2.7% for malt. There was no association between wheat sensitization and age at diagnosis, time of GFD, small bowel biopsy characteristics, allergy history, and gluten consumption. There was no relationship between sensitization to wheat and occurrence of immediate symptoms when not complying with GFD. <b><i>Conclusion:</i></b> In conclusion, the frequency of sensitization to wheat, rye, barley, and malt in CD patients was 4, 10.8, 5.4, and 2.7%, respectively. Therefore, to ensure that cutaneous and respiratory contact with wheat is safe, we advise patients with CD to investigate their sensitivity to wheat, rye, and barley because not all patients with CD are allergic to these cereals.

scholarly journals Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Yu-Ling Chen ◽  
Chien-Hung Chen ◽  
Rey-Heng Hu ◽  
Ming-Chih Ho ◽  
Yung-Ming Jeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Size ◽  
Poor Prognosis ◽  
Characteristic Curve ◽  
Tumor Grade ◽  
Serum Levels ◽  
Tumor Stage ◽  
High Serum ◽  
Term Survival ◽  
Preoperative Serum

Serum levels of the tumor marker CA19-9 have been reported to be elevated in patients with hepatocellular carcinoma (HCC), but its clinicopathologic significance is still unknown. A cohort of 304 patients undergoing surgical resection for HCC and having preoperative CA19-9 data was enrolled in this study. Serum CA19-9 levels were correlated with clinicopathologic factors. Univariate and multivariate analyses were performed to determine the predictors of patient survival. On receiver operating characteristic curve analysis, the cut off value of CA19-9 was determined to be 27 U/mL. One hundred and six patients had preoperative CA19-9 values >27 U/mL. High serum CA19-9 levels did not correlate with patient age, sex, viral status,α-fetoprotein level, tumor size, tumor grade, tumor stage, multiplicity, and vascular invasion. Patients with elevated preoperative CA19-9 levels had lower 10-year survival than those without CA19-9 elevation. Multivariate analysis revealed that CA19-9 level, tumor grade, and tumor size are independent prognostic factors for long-term survival. In conclusion, a preoperative CA19-9 value >27 U/mL is associated with poor prognosis after resection for HCC.

Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4766-4766
Author(s):  
Benjamin Kasenda ◽  
Marcel Rehberg ◽  
Melanie Franzem ◽  
Kristina Fritsch ◽  
Anna Markert ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Tumor Size ◽  
Conflicts Of Interest ◽  
Elimination Rate ◽  
Real Life ◽  
Central Nervous System Lymphoma ◽  
Serum Levels ◽  
High Dose ◽  
Complex Interplay ◽  
Leucovorin Rescue

Abstract Abstract 4766 Introduction Optimization of doses and administration schedules for anticancer drugs is crucial for effective and safe treatment. Since chemotherapy (CT) remains based predominately on empiric data, the creation of a mathematical model describing the complex interplay between dosing, tumor-response, agents' clearance, and toxicity, presents the opportunity to optimize treatment strategies of established but also new drugs. Primary central nervous system lymphoma (PCNSL) is a rare disease whose incidence is rising. Standard treatment of methotrexat (MTX) based CT has been approved in several studies. Here we report the most recent development of a real-life mathematical model describing the relationship between MTX serum levels and myelosuppression to optimize current treatment protocols. Materials and Methods We retrospectively analyzed 38 patients (pts) diagnosed and treated for PCNSL from 2005-2009. Pts <65 yrs of age were treated according to the high-dose MTX induction protocol (MTX 8g/m2/4hrs followed by leucovorin rescue), whereas treatment of pts >65 yrs of age followed the elderly protocol (MTX 3g/m2/4hrs followed by leucovorin rescue). Leukocyte and MTX serum levels were documented. We used an extended version of the mathematical model by Friberg et al. (J Clin Oncol 2002) as basis for our computations. The model was fitted to the data by using a least-squares-error approach. Results First order elimination proves sufficient for describing the pharmacokinetics of MTX. The average elimination rate is 0.25 h-1 with similar inter-patient and inter-therapy variation: the STD is 0.03 h-1 among patients and 0.02 h-1 among treatments. Similar analysis of all present parameters highlights the overall robustness of our approach. Conclusion Our model makes it possible to predict myelosuppression after treatment with MTX following leucovorin rescue based on clinical data. The parameters estimated are in accordance with those provided by Friberg et al. and thus confirm the model's general relevance. Extensions of the model describing tumor size reduction by MTX will be implemented to describe the complex interplay between MTX serum levels, clearance and anti-tumor effect. Additionally, mathematical optimal control theory methods will be employed to compute optimized schedules, i.e. doses and timing for the drugs that minimize tumor size and do not violate toxicity constraints such as leukocyte count. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Syndrome of Reduced Sensitivity to Thyroid Hormones: Two Case Reports and a Literature Review

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Anastasios Anyfantakis ◽  
Dimitrios Anyfantakis ◽  
Irene Vourliotaki
Keyword(s):  
Thyroid Hormone ◽  
Multinodular Goiter ◽  
Target Genes ◽  
Case Reports ◽  
Serum Levels ◽  
Free T4 ◽  
Laboratory Findings ◽  
Toxic Multinodular Goiter ◽  
High Doses ◽  
Primary Hyperthyroidism

Resistance to thyroid hormone (RTH) is an extremely rare dominantly inherited condition of impaired tissue responsiveness to thyroid hormone (TH). Most patients with RTH have mutations in the gene that encodes theβisoform of the receptor of thyroid hormone (THR-βgene). Mutant receptors are unable to activate or repress target genes. The majority of them are asymptomatic or rarely have hypo- or hyperthyroidism. RTH is suspected by the finding of persistent elevation of serum levels of free T3 (FT3) and free T4 (FT4) and nonsuppressed TSH. We present two cases of RTH diagnosed after total thyroidectomy. The first patient was initially diagnosed with primary hyperthyroidism due to toxic multinodular goiter. The second patient had undergone thyroidectomy for multinodular goiter 16 years before diagnosis of RTH. After thyroidectomy, although on relatively high doses of levothyroxine, both of them presented with the laboratory findings of RTH. Genetic analysis revealed RTH.

scholarly journals Meropenem-induced Valproic Acid Elimination: A Case Report of Clinically Relevant Drug Interaction

2017 ◽  
Vol 118 (2-3) ◽  
pp. 105-109 ◽  
Author(s):  
Martin Šíma ◽  
Jan Hartinger ◽  
Jan Rulíšek ◽  
Robert Šachl ◽  
Ondřej Slanař
Keyword(s):  
Valproic Acid ◽  
Drug Interaction ◽  
Case Report ◽  
Serum Concentration ◽  
Dose Escalation ◽  
Treated Patient ◽  
Case Reports ◽  
Concomitant Administration ◽  
Serum Levels ◽  
Population Kinetic

We present two case reports of drug interaction between valproic acid and meropenem. In comparison with expected population-kinetic based serum levels, we observed 90.8 and 93.5% decrease in valproic acid serum levels during concomitant administration with meropenem. If carbapenems need to be administered to valproic acid treated patient, other anticonvulsant addition seems to be the appropriate as most probably the valproic acid dose escalation would not be sufficient to achieve therapeutic serum concentration.

Researches for the Effects and Mechanisms of Recombinant Human Erythropoietin Administrated in BALB/c Murine Models with Multiple Myeloma.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4929-4929
Author(s):  
Caigang Xu ◽  
Yu Liu ◽  
Juan Xu ◽  
Meiyu Zhou
Keyword(s):  
Multiple Myeloma ◽  
Placebo Group ◽  
Tumor Size ◽  
Serum Levels ◽  
Monoclonal Immunoglobulin ◽  
Treatment Groups ◽  
Tumor Bearing ◽  
Spearman's Rho ◽  
Tnf Α ◽  
Individual Survival

Abstract Abstract 4929 Background Multiple myeloma myeloma accounts for approximately 1 percent of all cancers and 10 percent of hematologic cancers. It is incurable with conventional chemotherapy. Recent studies suggest that rHuEpo has additional biological effects which significantly prolonged the expected survival of six end-stage multiple myeloma (MM) patients and led to hypothesize that Epo might have an anti-neoplastic or anti-myeloma effect. This latter observation was further supported by studies. Objective Based on the myeloma models which established in BALB/c murine with MPC-11 myeloma cell line, our study is to verify the true effects, to research the suitable dose and administration way of recombinant human erythropietin(rHuEPO) for individuals with MM, as well as the possible antitumor mechanism in BALB/c murine myeloma models. Methods 550 healthful BALB/c mice were injected s.c. with 6×105 MPC-11 cells to establish the multiple myeloma models. When small palpable tumors were observed, the tumor-bearing mice were randomizedly divided into five groups which were respectively administrated the various rHuEPO doses (10,20,30,40 and 50 units per injection) and a placebo group with the saline. In the study, rHuEPO treatment was strated in 5 days after the initial MPC-11 cells injection, daily s.c. injections of rHuEPO for 30 consecutive days, followed by one injection per week for 4 weeks with a same dose as before. Hemoglobin, serum IL-6 and TNF-α were monitored before the start of rHuEPO administration and in 15 days, 30 days and 60 days after the start of rHuEPO administration. Immunofixation electrophoresis(IFE) was performed to detect the existence of the serum monoclonal immunoglobulin before the rHuEPO treatment and in 60 days after the rHuEPO-treatment. In the second part of the study, microvessel density(MVD) and TdT-mediated dUTP nick end labeling (TUNEL) techniques were performed to evaluate the tumor proliferation burden and tumor cell apoptosis respectively. Tumor volume change was monitored twice a week and weight change of tumour-bearing mice was measured once a week for every individual mouse during the whole study. Results The serum monoclonal immunoglobulin appeared in 12 days after the initial MPC-11 cells injection. There wasn't a significant decrease in tumor size of bearing cancer mice after administration of rHuEPO, and there was no significant difference among each dosage group. rHuEPO can obviously increase Hb levels in bearing cancer mice. The mice with a smaller tumor size had a higher Hb level, which resulting in a longer survival. Individual survival showed a significant positive correlation with Hb level (Spearman's rho 0.821, p=0.000), and in contrast, it had a negative correlation with tumor size (Spearman's rho  0.475, p=0.009). The serum levels of IL-6 showed no significant differences between the each rHuEPO treatment group and the placebo group, and the result was the same in the serum levels of TNF-α. Also, there is no difference in MVD between the treatment groups and placebo group. The apoptotic index of the treatment groups with rHuEPO seemed a little higher than that of the placebo group. Conclusion rHuEPO administration to the tumor-bearing mice seemed to prolong their individual survival. Insufficient evidence was found for the anti-MM therapeutic role of rHuEPO in our study. Disclosures No relevant conflicts of interest to declare.

A case of alpha-fetoprotein–producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman

2006 ◽  
Vol 16 (3) ◽  
pp. 1442-1445
Author(s):  
K. Takeuchi ◽  
S. Kitazawa ◽  
S. Hamanishi ◽  
M. Inagaki ◽  
K. Murata
Keyword(s):  
Postmenopausal Woman ◽  
Vaginal Bleeding ◽  
Pap Smear ◽  
Case Reports ◽  
Unknown Origin ◽  
Serum Levels ◽  
Alpha Fetoprotein ◽  
Endometrioid Adenocarcinoma ◽  
Eosinophilic Cytoplasm ◽  
Abnormal Vaginal Bleeding

Although case reports of alpha-fetoprotein (AFP)–producing adenocarcinoma other than hepatocellular carcinoma have gradually increased in number, AFP-producing adenocarcinoma of the endometrium is very rare. The patients universally complain of abnormal vaginal bleeding. The patient presented with complaints of epigastric discomfort. No vaginal bleeding was observed. Serum AFP concentration was 453 ng/mL, and lens culinaris agglutinin–reactive AFP percentage of total AFP was increased to 67%. Radiologic imaging and endoscopy did not provide evidence of any primary carcinoma in the liver and gastrointestinal tract. To investigate the unknown origin of high AFP, Pap smear of the endometrium followed by fractional curettage was performed and revealed adenocarcinoma of the endometrium. Radical hysterectomy with pelvic lymph node dissection and partial omentectomy was performed. Histologic study showed a mixture of major AFP-negative endometrioid adenocarcinoma and minor medullary proliferation of the AFP-positive hepatoid adenocarcinoma cells with eosinophilic cytoplasm and hyaline globules. After the surgery followed by four courses of weekly carboplatin and paclitaxel administration, serum levels of AFP dropped into normal range. The possible existence of AFP-producing adenocarcinoma of the endometrium should be considered in a postmenopausal woman even if there is no vaginal bleeding, when AFP-producing tumor is clinically suspected and the imaging studies fail to confirm the diagnosis.

Papillary Tumor of the Pineal Region: Systematic Review and Analysis of Prognostic Factors

Neurosurgery ◽  
2019 ◽  
Vol 85 (3) ◽  
pp. E420-E429 ◽  
Author(s):  
Vitor Nagai Yamaki ◽  
Davi Jorge Fontoura Solla ◽  
Renan Ribeiro Ribeiro ◽  
Saul Almeida da Silva ◽  
Manoel Jacobsen Teixeira ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Tumor Size ◽  
Cox Regression ◽  
Case Reports ◽  
Treatment Options ◽  
Multivariable Analysis ◽  
Case Series ◽  
Pineal Region ◽  
Biological Behavior ◽  
Final Sample

Abstract BACKGROUND Clinical outcomes and biological behavior of papillary tumors of the pineal region (PTPR) are still under investigation. The best therapeutic strategy has not been defined. OBJECTIVE To perform a comprehensive patient-level analysis of all PTPR cases and identify their clinical features, treatment options, and prognostic factors. METHODS A search of the medical databases for case series and reports on PTPRs from January 2003 to June 2017 was performed. Data addressing PTPR’s clinical presentation, imaging, treatment, and histological features were. Variables associated with the primary outcome of 36-mo survival were identified through Cox regression models. RESULTS The initial search yielded 1164 studies, of which 71 were included (60 case reports and 11 case series), containing 177 patients (mean age 33.0 ± 15.3 yr and 53.2% male). Intracranial hypertension and hydrocephalus prevailed as the clinical picture. Surgery was performed on 82.0% and gross total resection (GTR) was achieved on 71.4%. A total of 56.8% recurred after a median 29 mo (quartiles 10.5-45.5). The 36-mo survival rate was 83.5% (95% confidence interval [CI] 76.2-89.2%). Good functional outcomes (Glasgow Outcome Scale 4/5) were observed in 60.0%. The variables of interest were inconsistently reported and the multivariable analysis final sample was 133 patients. After adjustment for age, tumor size (each additional centimeter, hazard ratio [HR] 1.99, 95% CI 1.12-3.53, P = .019) and surgical treatment (HR 0.16, 95% CI 0.05-0.45, P = .001) were associated with 36-mo survival. CONCLUSION Tumor size and surgery are associated with improvement in 36-mo survival. We did not observe any significant benefits from GTR or adjuvant treatments.

Sign in / Sign up

Export Citation Format

Share Document